Futibatinib, a type VI pan-FGFR inhibitor, is recently FDA-approved for previously-treated, unresectable, locally-advanced, or metastatic iCCA with FGFR2 fusions or other rearrangements [26]. This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.